knowledge -WSS

knowledge

author：knowledge 2025-10-02 22:26:18 - browse：721

Illustration oh researchers look up at a blister pill pac. Part of the blister pack is filled with pills, while the center shows a sketch of a brain. -- biotech coverage from STAT — Mike Reddy for STAT

One by one, the companies behind Zoloft, Prozac, and Paxil soured on psychiatry.

It was the early 2000s, and as America warmed to the sounds of Sisqó and Shakira, the world’s largest pharmaceutical firms were running out of ideas to treat mental illness. Their blockbuster treatments for depression and schizophrenia had reshaped society and made billions of dollars in the process, but the old cash cows were soon to go generic. Efforts to one-up the last generation of drugs mostly resulted in incremental changes to aging medicines. And when insurance companies balked at paying brand-name prices for extended-release generics, the money dried up and the industry moved out.

“The mindset of Big Pharma in those days was one pill for millions and millions of people,” said John LaMattina, who led Pfizer’s research division from 1999 to 2007. “Everyone was looking for the next Lipitor, and when that fizzled out, there was an exodus out of psychotherapeutic areas.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

knowledge

WSS

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

FDA's Woodcock to retire early next year

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Poor hospice wound care hurts patients and families

Astellas still sees hope in its gene therapy after four deaths

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

hotspot

knowledge

leisure time

Psychedelics group wrestles with new pharma identity

Surge of respiratory disease in China has likely explanation

Hepatitis C has a cure — but many Americans still lack access to it

PBM reforms clear House panel

BioMarin wins approval for gene therapy to treat hemophilia A

Astellas still sees hope in its gene therapy after four deaths

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

focus

Readout LOUD podcast: Live from the 2023 STAT Summit

Morphosys mixed study results for blood cancer drug

Hospitals look to new technology to keep health care workers safe

Questions loom on AstraZeneca cancer drug as safety concerns ebb

STAT Summit: The economic case for universal basic health care

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

knowledge

knowledge

hotspot

hotspot